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ABSTRACT
B-cell acute lymphoblastic leukemia (B-ALL) is a rare heterogeneous disease 
characterized by a block in lymphoid differentiation and a rapid clonal expansion of 
immature, non-functioning B cells. Adult B-ALL patients have a poor prognosis with less 
than 50% chance of survival after five years and a high relapse rate after allogeneic 
haematopoietic stem cell transplantation. Novel treatment approaches are required to 
improve the outcome for patients and the identification of B-ALL specific antigens are 
essential for the development of targeted immunotherapeutic treatments. 
We examined twelve potential target antigens for the immunotherapy of adult 
B-ALL. RT-PCR indicated that only survivin and WT1 were expressed in B-ALL patient 
samples (7/11 and 6/11, respectively) but not normal donor control samples (0/8). 
Real-time quantitative (RQ)-PCR showed that survivin was the only antigen whose 
transcript exhibited significantly higher expression in the B-ALL samples (n = 10) 
compared with healthy controls (n = 4)(p = 0.015). Immunolabelling detected SSX2, 
SSX2IP, survivin and WT1 protein expression in all ten B-ALL samples examined, 
but survivin was not detectable in healthy volunteer samples. To determine whether 
these findings were supported by the analyses of a larger cohort of patient samples, 
we performed metadata analysis on an already published microarray dataset. We 
found that only survivin was significantly over-expressed in B-ALL patients (n = 215) 
compared to healthy B-cell controls (n = 12)(p = 0.013). 
We have shown that survivin is frequently transcribed and translated in adult 
B-ALL, but not healthy donor samples, suggesting this may be a promising target 
patient group for survivin-mediated immunotherapy. 
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is 
characterized by an excess of lymphoblasts of either the 
B- or T-lineage. If untreated the disease progresses rapidly 
and can be fatal within weeks to months. Adult patients 
with ALL who have had an allogeneic haematopoietic 
stem cell transplant (allo-HSCT) have an improved overall 
survival (OS) rate of 27–65% compared with 15–45% in 
the absence of allo-HSCT [1–3]. While the improvement 
in survival post-allogeneic HSCT may in part be due to the 
use of intensive chemotherapy and radiotherapy (such as 
total body irradiation) as conditioning, there does appear to 
be an increased survival advantage following HSCT using 
reduced intensity conditioning schedules in older patients 
and those with co-morbid risk factors [4, 5]. This suggests 
that post-transplant mechanisms, probably immunological 
in nature, play an important role in disease control with 
graft versus leukemia (GvL) effective in the eradication of 
residual disease. The ‘GvL effect’ has been demonstrated 
in other haematological malignancies, particularly chronic 
myeloid leukemia (CML), acute myeloid leukemia 
(AML) and myeloma, with the identification of probable 
immunological targets such as minor histocompatibility 
antigens [6], tumor specific antigens [7] and cancer-testis 
antigens (CTAs) [8]. 
A number of therapies have been, and are being, 
developed to target CD19, CD20, CD22 and/or CD52 
on adult B-ALL patient blasts (recently reviewed in 
[9]). One of the most promising antibody therapies is 
blinatumab, which at the end of phase III clinical trials 
was shown to increase survival by months in patients with 
relapsed or refractory disease [10].  In addition, anti-CD19 
chimeric antigen receptor-modified T cells (CAR-T-19) 
therapies have been shown to be able to induce complete 
remissions [11]. Such studies demonstrate the potential for 
immunotherapy to treat patients with B-ALL, with novel 
antigens providing additional targets that can be used to 
stimulate immune-mediate escape variant destruction.
Our own previous studies of adult B-ALL CD8+ T 
cells and their recognition of known leukemia antigens/
epitopes therein [12] did not identify the same frequency/
presence of antigen-specific T-cell populations as myeloid 
leukemia patients at disease diagnosis. The large numbers 
of affected lymphoblasts in the bone marrow of patients 
with adult B-ALL patients may lead to a lack of immune 
competent B and T cells in the periphery and may explain 
the general lack of tumor antigens identified to date. We 
examined the expression of a panel of cancer antigens 
in adult B-ALL to determine whether any would be 
promising targets for the immunotherapy of this difficult 
to treat disease.
RESULTS
Reverse transcription-polymerase chain reaction 
(RT-PCR) analysis of cell lines, patient samples 
and healthy donors 
We examined the expression of twelve antigens 
(BCP-20, G250, HAGE, END, NY-ESO-1, PASD1, 
p68 RNA helicase, SSX2, SSX2IP, survivin, tyrosinase 
and WT1), identified as promising through a review of 
the literature, in human cancer cell lines to demonstrate 
consistency with previously published data and to 
optimise our assays (Supplementary Table 1).  These 
results provided positive and negative controls for the 
expression of each antigen (Table 2A). We then examined 
the expression of the same twelve antigens in thirteen 
samples from eleven adult B-ALL patients (including 
twelve  samples taken from patients prior to the start 
of any treatment) and eight healthy volunteers (Table 
1). No suitable sample was available from ALL003 for 
RT-PCR analysis. RT-PCR analysis showed that two 
antigens were expressed in B-ALL patient samples 
(Table 2B) but not healthy donor samples. These were 
survivin (7/11 B-ALL patients) and WT1 (6/11 B-ALL 
patients) with no detectable antigen expression in eight 
healthy volunteer samples (Figure 1; Table 2B). All 
other genes studied (BCP-20, END, G250, HAGE, NY-
ESO-1, p68 RNA helicase, SSX2IP and tyrosinase) were 
detectable in patient samples and healthy volunteers, 
except PAS domain-containing protein 1 (PASD1) and 
SSX2 which were not detected in either. Due to limited 
sample availability we choose six of the antigens, that 
were differentially expressed in patients compared with 
normal controls (Survivin, WT1 and END) or of particular 
interest to our group (PASD1, SSX2, SSX2IP), for further 
investigation by qPCR. 
qPCR analysis of antigen expression in B-ALL 
and healthy donor samples
 A two-way ANOVA test was used to determine 
whether there was a statistical difference between 
transcript expression of END, PASD1, SSX2, SSX2IP, 
Survivin and WT1, as determined by qPCR, in B-ALL 
patients (ALL001-8, 11 and 14) compared with healthy 
volunteers. Survivin had a significantly higher expression 
in seven of the ten B-ALL patients analysed, compared 
to healthy controls (p = 0.015) (Figure 2A). Its median 
ΔCT value (7.19) in patients was much lower compared 
to the median ΔCT value (12.81) in normal controls. WT1 
was expressed by three out of ten adult B-ALL patients 
(Figure 2B) however the median ΔCT of B-ALL patients 
and normal controls, 12.88 and 12.81 respectively, 
were almost equal. Therefore, there was no significant 
difference detected by the two-way ANOVA test between 
these two groups. 
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Expression of PASD1 and synovial sarcoma, X 
breakpoint 2 (SSX2) expression were not detected in 
any of the adult B-ALL patients or healthy volunteers 
(Figures 2C and 2D). Nine out of ten patients expressed 
SSX2IP (Figure 2E) while seven out of ten expressed END 
(Figure 2F). Although the expression of these genes were 
high, their transcripts were also found in three of five 
healthy volunteers. 
Immunolabelling of antigen expression in B-ALL 
using immunocytochemistry
 The cell lines K562, OCI-LY3 and MDA-
MB-231 were used to demonstrate the effectiveness of 
immunolabelling to detect the expression of END, PASD1, 
SSX2, SSX2IP, survivin, and WT1 (Table 3). Four out of 
five antigens had a cytoplasmic and nuclear localisation, 
while WT1 was only found in the cytoplasm of the K562 
cells (Figure 3). The immunoreactivity score of both 
survivin and WT1 was moderate, while SSX2 and SSX2IP 
showed a weak labelling in K562 (Table 3). END was not 
expressed in the K562 cell line. OCI-LY-3 cell line was 
used as an extra control for the expression of PASD1 and 
showed high levels of PASD1 in the cytoplasm and near 
the cell membrane. END was moderately expressed on 
the surface of MDA-MB-231 cells grown on coverslips, 
confirming the findings of previous studies [13]. 
Actin was used as a positive control for ICC 
immunolabelling and, as expected, all patients and 
healthy volunteers had a moderate (30–143) to high 
immunoreactivity score (144–228) (Table 4). Two isotype 
matched control antibodies (Supplementary Table 2) 
or no primary antibody controls were used as negative 
controls to determine whether there was any non-specific 
staining. All patient samples (n = 10) expressed moderate 
to high levels of each antigen (SSX2, SSX2IP, Survivin 
and WT-1) while survivin expression was not detected 
in the healthy volunteer samples. In contrast, one of six 
Table 1A: Patient information 
ID Disease stage Age (at sampling) Sex
ALL001 Pre-treatment NK NK
ALL002 Follow-up 19 Male
ALL003 Pre-treatment 24 Male
ALL004 Diagnosis 22 Male
ALL005 Diagnosis 64 Male
ALL006 Pre-treatment 19 Male
ALL007 Diagnosis 19 Male
ALL008 Pre-treatment 19 Female
ALL009 Diagnosis 49 Male
ALL010 Diagnosis 19 Male
ALL011 Pre-treatment 18 Male
ALL012 Diagnosis 52 Female
ALL013 Pre-treatment 52 Male
 NK, not known.
Table 1B: Healthy control (all PB)
ID Age Sex
HV003 19 Male
HV004 NK NK
HV006 26 Female 
HV007 19 Male 
HV008 40 Female
HV016 26 Male 
HV021 NK Male 
HV032 NK NK
HV033 NK NK
NK, not known.
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Table 2: RT-PCR expression of the ten leukemia antigens of interest in (a) human cancer cell lines (b) adult B-ALL 
patient samples and healthy volunteers 
(a)
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697 + + – – – + – – – – – – – –
ARH77 + + + – – + – – – – + – – –
HeLa + + + – – + – + – – + – – +
H1299 + + + – + + + + – – + – – +
Jurkats + + – – + + – – – – – + – –
K562 + + + + + + – + + + + + – +
KG1 + + – – – + – – – – – + – –
KYO-1 + + + – – + – + – – – – – –
NB4 + + – – – + – + – – – – – +
P39 + + + + – + + – + – + + – +
SW480 + + – + – + – – – – + – – –
U266 + + + – – + – – – – + – – +
U937 + + – – – + – – – – – – – –
VLB + + + + – + – – + – + + –/+ +
Total 14/14 14/14 8/14 4/14 3/14 14/14 2/14 5/14 3/14 1/14 8/14 5/14 1/14 7/14
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Patient 
samples
ALL001 + + + + – + + – + – – – – +
ALL002 + + + + – – – – + – + + – +
ALL004 + + – + – – + – + – + – + –
ALL005 + + + – – – + – + – –/+ + – +
ALL006 + + + + + + + – + – + + – +
ALL007 + + – + – – + – + – + – – +
ALL008 + + – + – – – – – – – – – –
ALL009BM + + – + – – + – – – – + – –
ALL010BM + + + + + + + – + – + + + –
ALL010PB + + + + – – + – + – + + – –
ALL012BM + + + + – + – + – + + + –
ALL012PB + + – + – + + – + – + + – –
ALL013BM + + – + + – + – – – + + – +
Total‡ 11/11 11/11 6/11 10/11 3/11 4/11 9/11 0/11 9/11 0/11 8/11 7/11 3/11 5/11
HV 
samples 
(all PB)
HV003 + + + – –/+ + + – + – + – + –
HV004 + + – – – – – – – – – –
HV006 + + – – + – + – + – + – – –
HV007 + + – – – – – – – – – – – –
HV016 + + – – – – – – – – – – – –
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healthy volunteers expressed SSX2 at High levels, two of 
six healthy volunteers had detectable SSX2IP expression 
detectable at moderate levels, and WT1 at moderate 
levels. The ICC experiments were performed twice, with 
controls, due to limited samples being available, but the 
results were reproducible. 
Gene expression analysis
Bioinformatic analysis of the publically available 
gene expression data set GSE38403 [14], indicated that 
survivin (p = 0.013) was significantly over-expressed in 
the B-ALL patient cohort (n = 215) compared to healthy 
B-cell controls (n = 12). Furthermore, of the twelve 
candidate genes investigated only p68 DNA helicase, 
SSX2IP, Survivin and WT1 showed significant differences 
in expression when compared across individual 
cytogenetic groups (Table 5). Elevated END or survivin 
expression was significantly associated with the t(9;21) 
translocation while p68 DNA helicase, SSX2IP, Survivin 
and WT1 expression were associated with different 11q23 
/MLL abnormalities. We did examine whether there was 
a correlation between OS and event free survival (EFS) 
with the expression of each gene but none achieved 
significance and the closest to achieving significance was 
SSX2 interacting protein (SSX2IP) with an association 
with OS with a p value of 0.078.
DISCUSSION
Most patients with adult B-ALL achieve first 
remission with conventional treatment however many 
relapse with high associated mortality. There is an acute 
need for therapies that can remove minimal residual 
disease and delay, if not prevent, relapse for these patients. 
To this end, we have investigated twelve known leukemia 
antigens for their expression in adult B-ALL. 
Figure 1: Expression of transcripts encoding leukemia antigens in cell lines, primary adult B-ALL patients and 
normal donors. β-actin was used as a positive control for the ability of primers to amplify the cDNA. N was a no (cDNA) template 
control. Right hand side labels indicate expected product size and M indicates the location of the 1kB marker (HyperLadder I). RT-PCR 
data is representative of at least two independent experiments.
HV021 + + + – –+ + + – + – + – + –
HV032 + + – – – – – – – – – – – –
HV033 + + – – – – – – – – – – – –
Total 8/8 8/8 2/8 0/8 3/8 2/8 3/8 0/8 3/8 0/8 3/8 0/8 3/8 0/8
BM: bone marrow; HV: healthy volunteer; PB: peripheral blood. †: controls for the integrity of the cDNA samples for PCR 
amplification; ‡number of patients with antigen positive samples (n = 11) encompassing the analysis of 13 samples.
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Figure 3: Immunolabelling of the key antigens of interest in two primary adult B-ALL patient samples. Brown precipitate 
indicates the immunlabelling of test protein in the cell. Actin acted as the positive control for the assay. Two isotype control antibodies (Ms 
and Rb isotype) were used as negative controls to ensure there was minimal non-specific antibody binding to antigen. All pictures were 
taken at 400X magnification and were representative of at least two independent experiments.
Figure 2: Relative expression of transcripts encoding each antigen in the B-ALL patients compared to the healthy 
volunteers. Dots indicate the ΔCT values, whereby the CT of the endogenous control GAPDH is subtracted from the CT of each gene. 
Genes that were not expressed were assigned a CT value of 40. The higher the ΔCT value, the less antigen was expressed. All ΔCT values for 
antigens were lower level than the reference gene GAPDH. Streaked dots, representing patient sample ALL004, were outliers that do not 
represent antigen expression. P-values were determined using a two-way ANOVA test. Ns, not significant.
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Table 3: Frequency of immunolabelling of the six antigens of interest in K562, OCI-LY-3 and MDA-MB-23 cells.
Staining intensity Stained cells per microscopic image (%)
Immunoreactivity
score Subcellular localisation
K562 OCI-LY-3
MDA-
MB-231 K562 OCI-LY-3
MDA-
MB-231 K562 OCI-LY-3
MDA-
MB-231 K562 OCI-LY-3
MDA-
MB-231
Actin 4 4 4 185/203 (91)
563/569 
(99)
53/53 
(100)
364 
(Very high)
396 
(Very high)
400 
(Very high)
Cytoplasm, 
nucleus
Cytoplasm, 
nucleus
Cytoplasm, 
nucleus
END 0 ND 3 0 (0) ND 5/45 (11.1)
0 
(Negative) ND
33 
(Moderate) ND ND Surface
PASD1 2 3 ND 18/261 (6.9)
181/292 
(62) ND
14 
(Weak)
186 
(High) ND
Cytoplasm, 
nucleus
Surface, 
cytoplasm ND
SSX2 2 0 ND 23/255 (9)
0 
(0) ND
18 
(Weak)
0 
(Negative) ND
Cytoplasm, 
nucleus - ND
SSX2IP 2 1 ND 17/195 (8.7)
45/241 
(18.7) ND
17 
(Weak)
19 
(Weak) ND
Cytoplasm, 
nucleus Surface ND
Survivin 2.5 2.5 ND 71/190 (37.4)
67/364 
(18.4) ND 94 (Moderate)
46 
(Moderate) ND
Cytoplasm, 
nucleus
Cytoplasm, 
nucleus ND
WT1 2.5 1 ND 36/236 (15.3)
50/352 
(14.2) ND 38 (Moderate)
14 
(Weak) ND Cytoplasm Cytoplasm ND
Actin acted as positive control. Negative controls were cells only, two isotype and no primary antibody controls. Data was representative of two 
independent experiments. ND, not done.
Table 4: Immunoreactivity score for the antigens SSX2, survivin, SSX2IP and WT1 as detected by ICC in B-ALL 
patient samples and healthy donors
Patient 
number Cells only Controls#
Isotype 
Rabbit Actin SSX2 SSX2IP Survivin WT1
ALL001 0 0 0 96 83.5 (mod) 89.5 (mod) 82.5 (mod) 94.5 (mod)
ALL002 0 0 0 300 196 (high) 99.5 (mod) 89.5 (mod) 200 (high)
ALL003 0 0 0 98.5 187 (high) 200 (high) 98 (mod) 92.5 (mod)
ALL004 0 0 0 94.5 91 (mod) 96 (mod) 95.5 (mod) 84.5 (mod)
ALL005 0 0 0 198 188 (high) 178 (high) 93.5 (mod) 95.5 (mod)
ALL006 0 - 0 200 200 (high) 198 (high) 95.5 (mod) 96 (mod)
ALL007 0 0 0 200 198 (high) 200 (high) 186 (high) 96 (mod)
ALL008 0 0 0 200 84 (mod) 91 (mod) 89.5 (mod) 79 (mod)
ALL009 (BM) 0 0 0 197 188 (high) 176 (high) 195 (high) 181 (high)
ALL009 (PB) 0 0 0 200 171 (high) 90.5 (mod) 175 (high) 196 (high)
ALL010 (BM) 0 0 0 99 93 (mod) 95 (mod) 89 (mod) 99 (mod)
ALL010 (PB) 0 0 0 97.5 181 (high) 200 (high) 100 (mod) 100 (mod)
Total 0/10 0/10 0/10 10/10 10/10 10/10 10/10 10/10
HV003 0 0 0 273 0 0 0 35.5 (mod)
HV004 0 0 0 198 151.5 (high) 38 (mod) 0 0
HV007 0 0 0 267 0 0 0 0
HV008 0 0 0 187 0 0 0 0
HV016 0 0 0 288 0 0 0 64.5 (mod)
HV021 0 0 0 189 0 0 0 0
Total 0/6 0/6 0/6 6/6 1/6 1/6 0/6 2/6
Actin acted as a positive control. #The two isotype antibodies were used as negative controls or one isotype control and one 
test with no primary antibody. Immunoreactivity scores are as follows:- 0 = negative; 1–29:weak; 30–143: moderate (mod) 
and 144–228: high; >228: very high. Data is representative of at least two independent experiments.
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Survivin and WT1 were the only antigens detected 
in patients but not healthy volunteers by RT-PCR and ICC, 
but only survivin had a statistically significant elevation in 
expression between the adult B-ALL cohort and healthy 
volunteer group by qPCR. This adds to a growing body of 
studies that have shown an association between survivin 
expression and ALL. Survivin is upregulated in a large 
number of solid tumors and haematological malignancies, 
including AML and ALL [15]. It acts as a dual regulator 
of both apoptosis and cell cycle progression, and is a 
member of the inhibitors of apoptosis proteins (IAP) family. 
Survivin plays a role in the cells’ escape from apoptotic 
pathways and is considered an important mechanism that 
facilitates leukaemogenesis and the resistance of tumors to 
chemotherapy. Survivin overexpression has been shown to 
initiate haematologic malignancies in transgenic mice [16] 
while its synthesis and degradation is controlled in a cell 
cycle-dependent course, with increasing transcription during 
G1 that peaks in G2-M. This supports its role in the regulation 
of the mitotic spindle checkpoint [17]. A study by Esh and 
colleagues showed that the knockdown of survivin mRNA 
via short-hairpin RNA or a locked antisense oligonucleotide 
reduced its gene expression, increased apoptosis in leukemia 
cell lines and accumulated the cells in the sub-G1 phase of the 
cell cycle [18]. In addition, silencing of the survivin gene in 
an ALL xenograft animal model improved chemotherapeutic 
responses while overexpression of the survivin gene has been 
associated with poor prognosis in paediatric ALL patients 
[18]. Mori and colleagues examined survivin expression in 
ALL patients using RT-PCR and found survivin expression in 
11 of 16 ALL patients, but not in normal bone marrow (BM) 
cells [19]. Yang et al. also identified an elevation in vascular 
endothelial growth factor (VEGF) levels that coincided with 
survivin levels in 40 ALL patients by RT-PCR and western 
blotting [20]. 
Due to its limited expression in normal non-foetal 
tissues, survivin is a highly attractive immunotherapeutic 
target. When analysing five HLA-A2 positive adult ALL 
patient samples on a pMHC array [12] we did not detect 
any survivin-specific T cells that had bound to either of the 
HLA-A2 restricted survivin epitopes examined (survivin 
5–11 or 96–104; [21]) even at a detection sensitivity of 
at least 0.02% of the CD8+ population. However other 
groups have found that survivin-specific T cell responses 
can be expanded in a number of pre-clinical and clinical 
settings, most recently a Phase II multi-epitope vaccine 
of five survivin peptides with adjuvant that resulted in the 
expansion of survivin-specific T cell responses in patients 
with solid cancers [22]. Although survivin was listed as one 
of the top 15 prioritised antigens by virtue of its therapeutic 
function, immunogenicity, specificity and oncogenicity 
among other features [23], it has been shown to be 
downregulated in both chronic myeloid leukemia (CML) 
[24] and AML-derived leukaemic stem cells (LSCs) [25]. 
Although this negatively impacts the value of survivin for 
the immunotherapy of myeloid leukemia, it’s epitopes have 
been characterised for immunotherapy (recently reviewed 
in [26]) and are likely to be useful in the generation of anti-
tumor responses that may lead to epitope spreading and, at 
the least, could elongate the remission period and enable the 
administration of LSC-targeting treatments. 
Our previous serological analysis of recombinant 
tumor cDNA expression libraries (SEREX) analysis 
of AML patient sera, identified SSX2IP and PASD1, as 
well as SSX2IP’s interacting partner, SSX2, as potential 
targets for the immunotherapy of myeloid leukemia [27]. 
Both PASD1 and SSX2 are CTAs that are expressed in 
cancer cells and immunologically protected sites. This 
restricted expression makes CTAs attractive targets for 
immunotherapy as their targeting should not lead to 
catastrophic auto-immune responses against healthy tissue. 
However, PASD1 and SSX2 transcripts were not detected 
in any of the adult B-ALL patients or healthy controls, 
although all of the adult B-ALL patient samples examined 
showed positive immunolabelling for SSX2 at moderate 
to high levels. This indicates that SSX2 protein expression 
may be worthy of further investigation in B-ALL patient 
samples, and our results suggest a lack of correlation 
between detectable SSX2 transcription and the presence 
of SSX2 protein. 
Table 5: Microarray analysis indicating the significance of the association between the expression of each antigen 
and sample type, ALL compared with healthy pre B-cells and the presence or absence of cytogenetics abnormalities
p-value
Antigens Sampletype
Healthy preB 
cells vs. ALL
Cytogenetics 
abnormalities
NA vs. 
BCR/ABL†
NA vs. 
MLL/AF4†
NA vs. 
MLL_AF9†
NA vs. 
MLL_ENL†
NA vs. MLL_
EPS15†
SSX2IP NS NS 0.0038 NS 0.032 0.018 0.043 NS
P68 RNA Helicase NS NS 0.0256 NS NS 0.003 NS NS
WT1 NS NS 4.23E-11 NS 4.65E-06 0.026 0.0005 0.01
SURVIVIN 0.015 0.015 0.0035 0.003 NS 0.024 NS 0.023
Only those antigens that had a significant association between their expression and the clinical features analysed are shown.
NA: no abnormality; NS: not significant †: single cytogenetic abnormalities.
** - highly significant.
*** - very highly significant.
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In contrast to our own previous studies [27], 
SSX2IP transcripts were found in patient samples and 
healthy control PB by RT-PCR, and qPCR, suggesting an 
improved sensitivity in our detection of SSX2IP transcripts 
in the last decade, as the RT-PCR primers and reagents 
remained unchanged. Surprisingly NY-ESO-1 transcripts 
were also found in B-ALL patient samples and normal 
donor PB samples by RT-PCR. Both findings require 
further investigation but may reflect the rapid proliferation 
and enhanced turnover of the white blood cells compared 
with many other healthy cell types or a technical error on 
our part, although we used multiple controls to ensure 
we did not have any contaminating gDNA in our cDNA 
samples. In addition we used previously published primers 
with our own validated techniques. BCR/ABL, a hallmark 
of CML has also been found in 10–30% of tested healthy 
adults increasing in prevalence with donor age [28]. 
The Philadelphia chromosome translocation product has 
been shown to be essential for the development of CML 
yet remains present in healthy donors without doing so, 
suggesting an, as yet undefined, requirement for additional 
events to achieve full transformation to the malignant 
phenotype. Ismail et al. [29] suggested this occurrence 
was due to an accumulation of DNA damage with age 
and it may be a feature of the rapidly proliferating, high 
turnover “normal” white blood cells.  
Another of the potential immunotherapeutic targets 
for B-ALL that we investigated was the LAA WT1. Inoue 
et al. demonstrated consistently increased WT1 expression 
levels in most myeloid and lymphoid acute leukemias via 
RT-PCR [30].  These results were confirmed by Cilloni 
et al, who detected WT1 overexpression in all 48 ALL 
samples at diagnosis (BM and PB) when using qPCR [31]. 
They showed that WT1 expression was detectable, but that 
WT1 transcript levels in normal BM and PB were extremely 
low and often below the qPCR detection limit. Therefore, 
WT1 is a promising marker to discriminate between normal 
and leukaemic haematopoiesis, and effective in establishing 
the presence, persistence and/or reappearance of leukaemic 
blasts for diagnosis or detection of minimal residual disease 
(MRD).  Our qPCR results demonstrated WT1 mRNA 
expression in three out of the ten adult B-ALL patients, but 
none of the healthy volunteers. 
In summary, our study has demonstrated the value 
of pursuing survivin as a target for the immunotherapy 
of adult B-ALL, through our demonstration of its 
transcription and translation as early as disease diagnosis. 
This is a rare disease with high associated mortality. 
The fact that most patients can achieve first remission 
provides a time point during which residual tumor cells 
may be targeted by immunotherapy. The reduction or, 
ideally, removal of MRD could provide an opportunity to 
extend, if not prevent, relapse benefitting patient survival. 
A number of clinical trials are underway that target 
survivin including those using immunotherapy protocols 
or survivin-inhibitors. Our study has identified a patient 
group who would likely benefit from their application and 
warrants further investigation.  
MATERIALS AND METHODS
Cell lines and patient samples
Human cancer cell lines were used to measure the 
expression of the antigens and optimise assays. All were 
obtained from ATCC (Sigma-Aldrich Co. Ltd) and grown 
in RPMI 1640 or DMEM media (Sigma-Aldrich Company 
Ltd., Dorset, U.K.) containing 10% foetal bovine serum 
(FBS) and 1% penicillin and streptomycin (both Thermo 
Fisher Scientific, Leicestershire, UK), in a humidified 
incubator at 37°C with 5% CO2. K562 was positive for the 
expression of most antigens examined (Supplementary 
Table 2) as described previously.
16 samples were collected from 14 adult 
B-ALL patients at various treatment time points, but 
predominantly diagnosis and pre-treatment (Table 1A), 
from the Departments of Haematology at University 
Hospital Southampton NHS FT, Portsmouth Hospitals 
NHS Trust and the Royal Devon and Exeter Foundation 
Trust following informed consent and local ethical 
approval (REC 07/H0606/88). Leukaemic blasts and 
mononuclear cells were isolated from PB and/or BM in 
EDTA. White blood cells were also isolated from age and 
sex-matched normal donor PB following informed consent 
and local ethical approval (LREC 228/02/T). 
Identification of antigens for study in B-ALL
Due to a lack of known antigens that can act as 
targets for the immunotherapy of B-ALL, we identified a 
list of antigens of potential interest for further study. We 
had previously identified PASD1, SSX2IP and HAGE 
expression in presentation AML [27, 32] and examined 
presentation acute leukemia patients for T cells that 
recognized epitopes within G250, NY-ESO-1, tyrosinase, 
p68 RNA helicase, WT1 and survivin [12]. We examined 
SSX2 because of its known interaction with SSX2IP [33], 
BCP-20 based on its expression in solid tumors [34] and 
END based on its detection in paediatric leukemia and 
association with patient outcome [35]. 
RT-PCR analysis of antigen expression in patient 
and normal donor samples
To evaluate the expression of the most promising 
antigens in normal and malignant tissues we isolated 
RNA from BM and PB samples using QIAGEN RNeasy 
kit (QIAGEN Ltd.). mRNA was DNase I treated (Roche 
Products Ltd, Herts, U.K.), cleaned using a RNeasy kit 
(Qiagen), checked on a 1% agarose-TBE gel and quantified 
using a spectrophotometer. We prepared cDNA using the 
MBI Fermentas RevertAid First Strand cDNA synthesis kit 
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(MBI Fermentas Ltd, Helena BioSciences Ltd, Sunderland, 
U.K.), utilising the random hexamer primers. 
To test the fidelity of the cDNA samples, each cDNA 
was subjected to β-actin PCR. All PCR amplifications 
were performed on 200 ng of cDNA, mRNA (to show 
no gDNA was present in the mRNA samples) or gDNA 
(to demonstrate that the amplification of gDNA led to 
a product of a larger size than cDNA). We used 12.5 µl 
ReadyMix Taq PCR reaction mix (Sigma) and 1.5 mM 
MgCl2 in a final volume of 25 µl and primers were used 
as described previously:-  BCP-20 [36], G250 [37], 
HAGE [32], NY-ESO-1 [38], PASD1 [27], p68 RNA 
helicase [39], SSX2 [40], SSX2IP [27], tyrosinase [41] 
and WT1 [42]. To detect survivin we used the forward: 
5-GATGACGACCCCATAGAGGAAC-3′ and reverse: 
5′- GGGTTAATTCTTCAAACTGCTTCT-3′ primers 
[43]. Two primers were designed using the Primer3 Output 
MIT educational tool (www.genome.wi.mit.edu) to flank 
introns and were assessed for specificity using BLAST 
web based programmes.  These were β-actin forward 
5′-CATGGATGATGATATCGCCGC-3′ and reverse 
5′-CCATCACGCCCTGGTGC-3′ and END forward 
5′-CCCTTCTCTAAGGAAGCGCA-3′ and reverse 5′- 
AGTTGCTGTCCGAAGGATGG-3′. PCR products were 
electrophoresed on 1% TBE-agarose gels and assessed 
following staining with 10 µg/ml ethidium bromide. 
Sequencing of PCR products
After gel electrophoresis of the PCR products and 
image capture, bands were excised from the agarose gel 
and placed in 1.5 ml sterile eppendorf tube. These products 
were extracted from the gel bands using the PCR gel 
extraction kit (Qiagen). Where available, products from 
three independent PCR reactions on the same template 
were sent for Sanger sequencing to the DNA sequencing 
facility at the University of Cambridge. We analysed 
each sequence using Finch TV software and BLASTN to 
compare similarity between the PCR products and their 
target cDNA sequences.
QPCR analysis
 QPCR was performed using SYBR Green 
technology with the QuantiTect Primer Assays and 
QuantiNova SYBR Green PCR kit (all Qiagen), to 
investigate the relative expression of six TAAs in ten 
adult B-ALL samples (ALL001-8, 11 and 14), as well as 
GAPDH as a control for sample loading and the quality of 
the cDNA. Each primer was tested on at least one human 
cancer cell line that was known to express the antigen of 
interest (Supplementary Table 2), based on previously 
published studies. To control for contamination within the 
qPCR reagents, a no cDNA control was included on every 
qPCR plate whereby cDNA was replaced by RNase-free 
H2O. In addition, each sample was plated in triplicate on 
the 96-well qPCR plate (Applied Biosystems, USA) to 
identify any outliers in the dataset. The reaction volumes 
were 10 µL 2X QuantiNova SYBR green PCR MM, 
0.1 µL ROX reference dye, 2 µL primer assay and 6.9 µL 
RNase-free H2O, making a total volume of 19 µL added to 
each well in the 96-well plate. 
The thermocycler (StepOne Plus Real-Time PCR 
system, Applied Biosystems) ran a heating step for 
2 minutes at 95°C, then 40 cycles were run, whereby each 
cycle was set to denature for 5 s at 95°C, and to anneal 
plus extend primers in a combined step for 10 s at 60°C. 
This was immediately followed by a melt curve stage of 
15 s at 95°C, 1 min at 60°C and 15 s at 95°C, to verify the 
specificity of the amplification, e.g. no non-specific primer 
dimer formation. Data was compared using StepOne 
software v2.0 (Applied Biosystems) and the comparative 
CT method [44]. When comparing antigen expression in 
B-ALL to healthy controls, the results were normalised 
with the GAPDH reference gene (ΔCT = CT antigen–CT 
GAPDH).  All qPCR data were analysed with a two-
way ANOVA test for pairwise comparisons, using Partek 
Genomic Software (Partek Inc., USA). 
Immunocytochemistry
Leukocytes were isolated following a 30min 
incubation of PB and/or BM samples with red cell lysis 
buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), 
after which leukocytes were pelleted by centrifugation 
for 10 min at 800 g. Leukocytes or cells from lines were 
resuspended in PBS at 5 × 106/ml, with 10 ul cells spotted 
at each of two sites on microscope glass slides. Slides were 
double wrapped in saran wrap and stored at –20oC until 
required for use. Immunocytochemistry was performed as 
described previously [45] using antibodies as detailed in 
Supplementary Table 1.
Due to the cellular localisation of END on the cell 
surface, the MDA-MB-231 cell line was grown to 50–70% 
confluence on glass coverslips. Then, the culture medium 
from each well was aspirated and cover slips were rinsed 
in PBS. The coverslips were air dried for 4–6 h, wrapped 
in saran wrap and stored in –20°C freezer. Actin was used 
as a positive control for the successful performance of 
ICC while isotype, no primary and no secondary antibody 
immunolabelling acted as negative controls, used to detect 
non-specific staining. Lillies-Mayer Haematoxylin was 
used as a countertstain.
Staining intensities were scored according to a five-
tiered scale described originally by [46] as follows:- 0: 
no staining; 1: background; 2: weak staining; 3: moderate 
staining; 4: strong staining. The percentage of positively 
stained cells was based on the cell count of stained cells 
per microscopic view, and represented on a five-tiered 
scale (0: 0%; 1: 1–10%; 2: 11–50%; 3: 51–80%; 4: > 80%). 
The final immunoreactivity score was obtained by 
multiplication of the percentage of positive stained cells 
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per microscopic view by the value for staining intensity 
(0 = negative, 1–29 = weak, 30–143 = moderate, 144–228 
= high and > 228 = very high staining) [47]. 
Gene expression analysis
To determine the relative expression of the antigens 
of interest in a larger cohort of adult B-ALL samples 
and healthy controls, we performed metadata analysis 
on a publically available microarray expression data 
(GSE38403) [14] which utilised 215 adult B-cell ALL and 
12 normal pre-B samples.  The CEL files were downloaded 
and imported in the Partek Genomic Suite, normalised 
using RMA, and subjected to ANOVA analysis which was 
filtered on significance for the generation of the gene lists.
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